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Abstract
Background: The amide class compound, 3, 4-dichloropropionanilide (DCPA) is known to affect
multiple signaling pathways in lymphocyte and macrophage including the inhibition of NF-κB ability.
However, little is known about the effect of DCPA in cancer cells. Hypoxia-inducible factor 1 (HIF-
1) regulates the expression of many genes including vascular endothelial growth factor (VEGF),
heme oxygenase 1, inducible nitric oxide synthase, aldolase, enolase, and lactate dehydrogenase A.
HIF-1 expression is associated with tumorigenesis and angiogenesis.
Methods: We used Transwell assay to study cell migration, and used immunoblotting to study
specific protein expression in the cells.
Results: In this report, we demonstrate that DCPA inhibited the migration and proliferation of
DU145 and PC-3 prostate cancer cells induced by serum, insulin, and insulin-like growth factor I
(IGF-I). We found that DCPA inhibited HIF-1 expression in a subunit-specific manner in these
cancer cell lines induced by serum and growth factors, and decreased HIF-1α expression by
affecting its protein stability.
Conclusion: DCPA can inhibit prostate cancer cell migration, proliferation, and HIF-1α
expression, suggesting that DCPA could be potentially used for therapeutic purpose for prostate
cancer in the future.
Background
The genetic alterations in human cancer are a major focus
of cancer research over the past two decades. Many genetic
alterations such as activation of oncogenes and inactiva-
tion of tumor suppression genes lead to the increased
expression of Hypoxia-inducible factor 1 (HIF-1) [1-4].
HIF-1 is a heterodimeric transcription factor composed of
HIF-1α and HIF-1β subunits [5,6]. HIF-1 regulates the
expression of many genes including vascular endothelial
growth factor (VEGF), heme oxygenase 1, inducible nitric
oxide synthase, aldolase, enolase, and lactate dehydroge-
nase A [7]. HIF-1 activity correlates with tumorigenesis
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and angiogenesis when wild type and HIF-1-deficient cell
lines levels were injected into nude mice [1,8]. HIF-1 is
overexpressed in many human cancers including prostate
cancer [9]. HIF-1 expression in prostate cancer cells is
induced by growth factors, and inhibited by phosphati-
dylinositol 3-kinase (PI3K) inhibitors and the tumor sup-
pressor PTEN [2,10].
The amide class compound, DCPA is a dichlorinated ring
compound of low molecular weight. Previous investiga-
tions on the effects of this compound on lymphocyte and
macrophage signaling pathways, reveal that this com-
pound reduces NF-κB DNA binding ability [11]. This cor-
relates with the down regulation of the production of a
number of proinflammatory cytokines, including tumor
necrosis factor-α, interleukin (IL)-6, IL-1β [11-13] as well
as IL-2 [14-17] DCPA also inhibits activation of key com-
ponents of the Ras pathway [17]. The noted down regula-
tion of the signaling pathways leads us to speculate that
DCPA may also affect these pathways in cancer cells in a
manner that could be exploited to provide a mode of
chemotherapy against these tumors. In this study, we
show that DCPA inhibited serum and growth factor-
induced cell migration and proliferation, and inhibited
HIF-1 expression induced by serum and growth factors in
prostate cancer cells. This study indicates that DCPA or its
analog may represent a new therapeutic agent for cancer
treatment due to its relatively low toxicity.
Methods
Cell culture
The human prostate cancer cell line, DU145, was cultured
in minimum essential medium (MEM) with Earle's salts
and glutamine (Gibco BRL, Grant Island, NY), supple-
mented with 10% fetal bovine serum (FBS) (Hyclone)
and 3% chicken serum (Gibco BRL, Grant Island, NY).
The human prostate cancer cell line, PC-3, was cultured in
F-12K nutrient mixture (Kaighn's modification) (Gibco
BRL), supplemented with 10% FBS and 1% chicken
serum. The cells were incubated at 37°C in 5% CO2 incu-
bator.
Cell migration assay
The DU145 and PC-3 cells were cultured in normal
medium overnight, then switched to serum-free MEM
medium in the presence or absence of DCPA for 18 h. The
cells were harvested in Hanks balanced salt solution with
5 mM EDTA and 25 mM HEPES, pH 7.2, washed, and
resuspended in serum-free medium (SFM). Cell migration
was assayed using a polystyrene Transwell plate (Corning
Costar, Cambridge, MA) with 6.5 mm diameter wells and
pore sizes of 8.0 μm. The wells were coated with 10 μg/ml
collagen type 1 (Upstate Biotechnology, Lake Placid, NY)
in 1× PBS buffer at 4°C overnight. The excess collagen was
removed from the bottom chambers after the incubation,
and replaced with 250 μl serum-free medium in the
absence or presence of DCPA (150 μM) or 10% FBS. The
cells were counted and diluted to 400,000 cells per ml in
SFM, and 250 μl of the cells were added to the top of each
well. For the DCPA treatment, the cells were incubated
with SFM with 150 μM DCPA 20 min prior to the addition
of 100,000 cells to each well in the presence or absence of
10% FBS in the bottom chambers, followed by the addi-
tion of 10% serum, 200 nM insulin, or 2 nM insulin-like
growth factor I (IGF-I) for 6 h. The wells were incubated at
37°C in 5% CO2incubator for 6 h. The wells were
removed, and the cells on the top of the well were wiped
out with a cotton swab, stained with 1% crystal violet in
0.1 M borate containing 2% ethanol, pH 9.0 for 20 min.
The migrated DU145 and PC-3 cells were rinsed with
water, dried, and counted using light microscope with 10×
magnification.
Cell viability assay
The DU145 and PC-3 cells were seeded at 5 × 105 cells per
well in a 24-well plate, and incubated at 37°C in 5% CO2
incubator in the complete medium for 24 h. Then, the cul-
ture medium was removed and replaced with serum-free
medium containing DCPA (25, 75 or 150 μM) or solvent
alone (ETOH). A medium-only control was also included.
After the culture in serum-free medium for 24 h, the cells
were switched to the medium with 10% serum for 6 h.
The cells were then stained with trypan blue, and counted
using standard hematocytometer methods.
Cell proliferation assay
One day before the assay, DU145 and PC-3 cells were
seeded at 100,000 cells per well in a six-well plate and
incubated at 37°C in 5% CO2 incubator in the medium as
described above. Then the cells were switched to fresh
medium containing DCPA (150 μM) or solvent alone (0
μM DCPA), and the cell number was counted 24, 48, and
72 h after the treatment using standard hematocytometer
methods.
Protein extraction and immunoblotting
DU145 and PC-3 cells were harvested in cold 1× PBS and
lysed on ice for 30 min in RIPA buffer (150 mM NaCl, 100
mM Tris, pH 8, 0.1% SDS, 1% Triton X-100, 1% sodium
deoxycholate, 5 mM EDTA and 10 mM NaF) supple-
mented with 1 mM sodium vanadate, 2 mM leupeptin, 2
mM aprotinin, 1 mM phenylmethylsulfonyl fluoride
(PMSF), 1 mM DTT, and 2 mM pepstatin A. The lysates
were cleared by centrifugation at 14,000 rpm for 15 min,
and the supernatants were collected as total cellular pro-
tein extracts. The protein concentration in the extracts was
determined using Bio-Rad protein assay reagent (Bio-Rad,
Richmond, CA). The protein extracts were separated by
SDS-polyacrylamide gel electrophoresis (SDS-PAGE), and
transferred to nitrocellulose membranes in 20 mM Tris-
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HCl (pH 8.0) containing 150 mM glycine and 20% (v/v)
methanol. Membranes were blocked with 5% nonfat dry
milk in 1× TBS containing 0.05% Tween 20 and incubated
with antibodies against HIF-1α and HIF-1β [18]. The pro-
tein bands were detected by the incubation with horserad-
ish peroxidase-conjugated antibodies (NEN, Boston,
MA), and visualized using the enhanced chemilumines-
cence reagent (NEN).
HIF-1α protein stability analysis
PC-3 cells were cultured in serum-free medium for 24 h,
followed by the incubation with medium containing 10%
fetal bovine serum for 5 h. Then the cells were treated with
solvent alone or 150 μM DCPA for 1 h, followed by the
incubation with 100 μM cycloheximide for 0 to 16 min.
Cellular lysates were subjected to immunoblotting using
antibodies against HIF-1α and HIF-1β. The intensity of
HIF-1α/HIF-1β protein signals was quantified using
EagleSight densitometry software (Version 3.21; Strata-
gene).
Statistical analysis
The results on DU145 and PC-3 cell migration and prolif-
eration were analyzed statistically using the Student-New-
man-Keuls multicomparisons test using SigmaStat
Software (SPSS Inc., Chicago, IL).
Results and discussion
DCPA inhibits prostate cancer cell migration
The hallmark of tumor cells is their ability to migrate and
metastasize. Prostate cancers are known to metastasize in
a high percentage of the cases, which is obviously linked
to a poor prognosis. Therefore, an agent that could inhibit
cell migration with relatively low toxicity would be of
benefit, likely as adjunct therapy to more traditional can-
cer drugs. To determine a potential effect of DCPA on can-
cer cell migration, cell migration on a collagen substrate
was tested using the prostate cancer cell lines, DU145 and
PC-3. The results demonstrated that the migration of
DU145 cells in medium with serum has two-fold greater
than that in serum-free medium (Fig. 1A). DCPA treat-
ment inhibits the cell migration more than two-fold as
compared to the solvent control in the presence or
absence of serum (Fig. 1A). In PC-3 cells, serum increased
the cell migration by 50% more than the serum-starved
cells (Fig. 1B). Similarly, DCPA inhibited the cell migra-
tion in the presence and absence of serum. These results
suggest that DCPA can inhibit the basal-level and serum-
induced cell migration.
To determine if the decreased cell migration was due to
decreased cell viability, cell viabilities were determine on
separate cultures treated as described above. As shown in
Fig. 1C, neither cell line showed any increase in cell death
over either the solvent (ETOH) or medium (nil) controls.
Thus, the inhibition of cell migration by DCPA is due to
the effect of DCPA on the signaling pathways associated
with cell motility and not simply due to increased cell
death.
DCPA inhibits cell proliferation
Unchecked proliferation is also a hallmark of cancer cells
that commonly exhibit increased proliferation when com-
pared to normal cells. To examine the effect of DCPA on
the proliferation of DU145 and PC-3 cells, we determined
the cell proliferation after the treatment for 24, 48, and 72
h. The cell number at 24 h culture was used as a baseline.
In the solvent control, the number of DU145 cells
increased by 50% and 100% at 48 h and 72 h, respec-
tively. However, cells cultured in the presence of DCPA
did not increase significantly throughout the 72 h culture
period (Fig. 2A). Similarly, DCPA treatment inhibited the
proliferation of PC-3 cells (Fig. 2B). PC-3 cells cultured in
the presence of solvent control showed 3-fold increase in
cell number over the 72 h period. However, PC-3 cells cul-
tured in the presence of DCAP showed no net change in
cell numbers over the 72 h period (Fig. 2B). These results
suggest that DCPA treatment is sufficient to inhibit the
cell proliferation.
DCPA treatment diminishes HIF-1α expression induced by 
serum
We previously showed that activation of oncogenes, v-Src
and PI3K, increased HIF-1 expression [1,2]. HIF-1 is well
established as a transcriptional regulator of VEGF and
many other genes involved in tumor growth and angio-
genesis [1,7,8]. HIF-1α expression is increased in prostate
cancer cells by the addition of serum [2,10]. We sought,
therefore, to determine whether DCPA affected HIF-1
expression induced by serum. DU145 and PC-3 cells were
cultured without serum for 18 h in the absence or pres-
ence of DCPA, then exposed to 10% serum for 6 h. Serum
significantly induced the expression of HIF-1α in DU145
cells (Fig. 3A), and in PC-3 cells (Fig. 3B). Serum did not
increase the levels of HIF-1β expression (Fig. 3). The addi-
tion of DCPA decreased the induction of HIF-1α expres-
sion by serum. The levels of HIF-1α expression were
diminished to below basal values by 150 μM DCPA in
DU145 cells (Fig. 3A). The levels of HIF-1β expression
were not affected by DCPA. This study indicated that
DCPA specifically inhibited HIF-1α expression induced
by serum.
HIF-1α expression is also up-regulated in response to
growth factor signaling [2,10]. In order to determine
whether DCPA could impede growth factor mediated up-
regulation of HIF-1α expression, cells were induced with
insulin and IGF-I in the presence or absence of DCPA. The
DU145 and PC-3 cells were cultured in the absence of
serum for 18 h, followed by the exposure of insulin or
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IGF-I for 6 h. HIF-1α expression in DU145 cells was sig-
nificantly induced by insulin and IGF-I, and the induced
HIF-1α expression was inhibited by DCPA (Figs. 4A and
4C). But HIF-1β expression was not affected by the addi-
tion of insulin and IGF-I or by the presence of DCPA (Figs.
4A and 4C). We also analyzed PC-3 cells for the compari-
son. HIF-1α expression in PC-3 cells was also greatly
induced by both insulin and IGF-I, and inhibited by the
addition of DCPA (Figs. 4B and 4D). In PC-3 cells, the
induction of HIF-1α expression by IGF-I was greater than
that by insulin (Figs. 4B and 4D). The expression of HIF-
1β was not affected in the same experiment. These results
suggest that DCPA affects HIF-1 expression in a subunit-
specific manner in prostate cancer cells, inhibits HIF-1α
expression induced by growth factors such as insulin and
IGF-I, and further suggest that DCPA may be a potential
Migration of prostate cancer cells was inhibited by DCPAFi ure 1
Migration of prostate cancer cells was inhibited by DCPA. Prostate cancer cells, DU145 (A) and PC-3 (B) cells, were cultured 
in serum-free medium in the presence (+) or absence (-) of 150 μM DCPA for 18 h as indicated. The cell migration assay was 
performed using Transwell migration chambers coated with 10 μg/ml collagen in the migration buffer with or without 10% fetal 
bovine serum for 6 h at 37°C as described in Materials and Methods. The migrated cells were counted, and data were 
expressed as mean of cell counts from replicate experiments. Bars, SD; * indicates significant difference when compared to cell 
migration without DCPA (P < 0.01). C. Viability of the prostate cancer cells was not affected by DCPA. The cells were cul-
tured in the absence or presence of DCPA for 24 h, and cell viability assay was performed as described in Materials and Meth-
ods. The results were expressed as the mean percentage of cells capable of excluding trypan blue. These experiments were 
repeated at least twice. Bars, SD.
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specific molecule to target the growth factor/HIF-1 path-
way for cancer therapy.
We demonstrated that DCPA specifically inhibits HIF-1α,
but not HIF-1β expression in prostate cancer cells. DCPA
may regulate HIF-1α expression by altering either the sta-
bility of HIF-1α protein, or by inhibiting its mRNA levels.
HIF-1α protein is known to interact with tumor suppres-
sors p53 and von Hippel-Lindau (VHL) protein [19].
Under normal oxygen tension, HIF-1α is degraded by pro-
teasome degradation pathway. Proteasomal degradation
is likewise regulated by p53 and VHL, which serve to
increase the efficiency of ubiquination of HIF-1α. Con-
versely, ubiquination of HIF-1α is decreased by hypoxia,
a condition commonly observed in tumors [20, 21]. To
determine whether DCPA treatment affected HIF-1α pro-
tein stability, PC-3 cells were treated with or without
DCPA in the presence of 100 μM cycloheximide, which
inhibits new protein synthesis in the cells. HIF-1α protein
stability was analyzed in the cells. DCPA treatment greatly
decreased the HIF-1α protein stability with 40% reduc-
tion of HIF-1α protein half-life in the cells (Fig. 5). DCPA
Expression of HIF-1α was specifically induced by the addition of serum, and inhibited by th  presence of DCPAFigu e 3
Expression of HIF-1α was specifically induced by the addition 
of serum, and inhibited by the presence of DCPA. DU145 
(A) and PC-3 (B) cells were cultured in serum-free MEM 
basal medium with Earle's salt in 0, 75, or 150 μM DCPA for 
24 h, followed by the incubation with or without 10% fetal 
bovine serum for 6 h. Total cellular protein extracts were 
prepared from these cells, and aliquots of the extracts (30 
μg) were used for the immunoblotting analysis using antibod-
ies against HIF-1α and HIF-1β.
HIF-1α
HIF-1β
Serum - +     +     +
A    DU145
75      150
DCPA
HIF-1α
HIF-1β
Serum - +     +     +
B    PC-3
75      150
DCPA
Proliferation of prostate cancer cells was inhibited by DCPAFigure 2
Proliferation of prostate cancer cells was inhibited by DCPA. 
DU145 (A) and PC-3 (B) cells were seeded at 100,000 cells 
per well one day before the addition of DCPA. The cells 
were incubated in the presence (+) or absence (-) of 150 μM 
DCPA for 24, 48, and 72 h, as indicated. The cell prolifera-
tion assay was performed as described in Materials and Meth-
ods. The results are expressed as mean of cell number from 
replicate experiments. Bars, SD. * indicates significant differ-
ence when compared to cell proliferation without DCPA at 
the same time point (P < 0.01).
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treatment did not affect HIF-1α mRNA level in the cells
(data not shown). This result suggests that DCPA treat-
ment may inhibit HIF-1α protein stability through the
proteasomal degradation pathway. To further confirm
this hypothesis, we treated the cells with DCPA in the
absence or presence of proteasome inhibitor MG132. The
presence of MG132 greatly increased HIF-1α protein lev-
els to much higher levels even in the presence of DCPA
than that in the serum treatment alone (Fig. 6), suggesting
that DCPA treatment inhibits HIF-1α protein expression
through the proteosomal degradation pathway. Although
the signaling pathways that control HIF-1α expression
mediated by DCPA are still unknown, it is possible that
HIF-1α expression is inhibited DCPA via the inhibition of
PI3K signaling pathway, which activates AKT [19]. It is
known that HIF-1α expression is inhibited by PI3K inhib-
itors and the tumor suppressor PTEN [2,10]. DCPA may
mimic PTEN to inhibit PI3K signaling and thus, HIF-1α
expression. AKT is also known to activate the transcription
factor NF-κB and DCPA down regulates NF-κB activation
[11]. DCPA also selectively inhibits proinflammatory
cytokines as well as IL-2 by down regulating transcription
[11-16]. Hypoxia condition is commonly observed during
tumor growth. To determine whether DCPA treatment
DCPA specifically inhibits expression of HIF-1α induced by insulin and IGF-IFigure 4
DCPA specifically inhibits expression of HIF-1α induced by insulin and IGF-I. DU145 (A) and PC-3 (B) cells were cultured in 
the basal medium without serum in the presence of 0, 75 or 150 μM DCPA for 24 h, followed by the incubation with (+) or 
without (-) 200 nM insulin for 6 h. The total cellular proteins were prepared from the cells, and used for the analysis of HIF-1α 
and HIF-1β protein expression as described above. DU145 (C) and PC-3 (D) cells were cultured in the basal medium without 
serum as above, followed by the incubation in the presence (+) or absence (-) of 2 nM IGF-I for 6 h. The HIF-1α and HIF-1β 
protein expression from the cells was analyzed by immunoblotting.
HIF-1α
HIF-1β
Insulin - +     +     +
A
75      150
DCPA
HIF-1α
HIF-1β
Insulin - +     +     +
B
75      150
DCPA
HIF-1α
HIF-1β
IGF-I - +     +     +
C
75      150
DCPA
HIF-1α
HIF-1β
IGF-I - +     +     +
D
75      150
DCPA
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affected hypoxia-induced HIF-1α expression, the cells
were cultured in the absence or presence of 1% O2 condi-
tion. DCPA treatment greatly inhibited hypoxia-induced
HIF-1α protein level (Fig. 7), suggesting that DCPA com-
monly inhibits certain signaling pathways for regulating
growth factor- and hypoxia-induced HIF-1α expression. It
is also possible that there may be a connection between
inhibition of HIF-1α expression and inhibition of cell
migration, which would be a very interesting topic for the
future study. These results indicate that DCPA may inhibit
prostate cancer cell migration, proliferation, and HIF-1α
expression through multiple signaling pathways.
Conclusion
In conclusion, these results demonstrated that DCPA
inhibits cell migration, proliferation, and HIF-1α expres-
sion in prostate cancer cells. To further understand the
molecular mechanism of DCPA in decreasing HIF-1α
expression in these cells, we found that 1) DCPA specifi-
cally inhibits the induction of HIF-1α expression by
serum, 2) expression of HIF-1β is not altered by the addi-
tion of serum or DCPA, 3) the effect of DCPA on HIF-1α
is not due to the non-specific effect in the cells, 4) DCPA
treatment decreased HIF-1α expression by affecting its sta-
bility through the proteasomal degradation pathway, and
5) DCPA also inhibited hypoxia-induced HIF-1α expres-
sion in human prostate cancer cells.
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Abbreviations: DCPA, n-3, 4-dichlorophenyl propana-
mide; FBS, fetal bovine serum; HIF-1, Hypoxia-inducible
factor 1; IL, Interleukin; IGF-I, insulin-like growth factor I;
MEM, Minimum Essential Medium; PI3K, phosphatidyli-
nositol 3-kinase; SFM, serum-free medium; VEGF, vascu-
lar endothelial growth factor.
MG132 treatment prevented the inhibition of HIF-1α expression by DCPAFigure 6
MG132 treatment prevented the inhibition of HIF-1α 
expression by DCPA. DU145 (A) and PC-3 (B) cells were 
cultured in serum-free MEM basal medium with Earle's salt in 
the presence of 0, 75, or 150 μM DCPA for 24 h, followed 
by the treatment with or without 10 μM of MG132 for 30 
min. Cells were incubated with or without 10% fetal bovine 
serum for 6 h. Total cellular protein extracts were prepared 
from these cells, and aliquots of the extracts (30 μg) were 
used for the immunoblotting analysis using antibodies against 
HIF-1α and HIF-1β.
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Effect of DCPA on HIF-1α protein stabilityFigure 5
Effect of DCPA on HIF-1α protein stability. A. PC-3 cells 
were cultured in serum-free medium for 24 h, followed by 
the incubation with 10% fetal bovine serum for 5 h. Then the 
cells were treated with solvent alone (CHX, top panel) or 
150 μM DCPA (CHX+DCPA, bottom panel) for 1 h, fol-
lowed by the incubation with 100 μM cycloheximide for 0 to 
16 min. Cellular lysates were subjected to immunoblotting 
using antibodies against HIF-1α and HIF-1β. B. The intensity 
of HIF-1α protein signals obtained above was quantified from 
three replicate experiments using EagleSight densitometry 
software (Version 3.21; Stratagene). The densitometry data 
were the ratio of HIF-1α/HIF-1β, and normalized to that of 
the control (0 min).
CHX
CHX
+DCPA
Min       0       2       4       8      16   
HIF-1α
HIF-1β
HIF-1β
HIF-1α
A
Time (min)
R
el
at
iv
e 
H
IF
-1
α
le
ve
l
B
0
0.2
0.4
0.6
0.8
1
1.2
0 2 4 8 16
Solvent (t1/2=3 min)
150 μM DCPA (t1/2=1.85 min)
BMC Cancer 2006, 6:204 http://www.biomedcentral.com/1471-2407/6/204
Page 8 of 8
(page number not for citation purposes)
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
BHJ performed initial experiments in this study and the
overall supervision of the project, and drafted the manu-
script; LZL acquired the data for Figs. 5, 6, 7; RS and DCF
participated in the design of the study and manuscript
preparation; and JBB participated in the design of the
study, data interpretation and manuscript preparation. All
authors read and approved the final version of the manu-
script.
Acknowledgements
This study was supported by NIH Grants ES07512, ES011311, CA109460; 
and American Cancer Society Research Scholar Grant 04-076-01-TBE. We 
are grateful to Zongxian Cao, Jenny Z. Zheng, Linda Corum, and Cheryl 
Walton for their technical assistance.
References
1. Jiang BH, Agani F, Passaniti A, Semenza GL: V-SRC induces expres-
sion of hypoxia-inducible factor 1 (HIF-1) and transcription
of genes encoding vascular endothelial growth factor and
enolase 1: involvement of HIF-1 in tumor progression.  Cancer
Res 1997, 57:5328-5335.
2. Jiang BH, Rue E, Wang GL, Roe R, Semenza GL: Dimerization,
DNA binding, and transactivation properties of hypoxia-
inducible factor 1.  J Biol Chem 1996, 271:17771-17778.
3. Semenza GL: HIF-1, O2, and the 3 PHDs: How Animal Cells
Signal Hypoxia to the Nucleus.  Cell 2001, 107:1-3.
4. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D,
Buechler P, Isaacs WB, Semenza GL, Simons JW: Overexpression
of hypoxia-inducible factor 1alpha in common human can-
cers and their metastases.  Cancer Res 1999, 59:5830-5835.
5. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, Vogt PK: Phosphatidyli-
nositol 3-kinase signaling controls levels of hypoxia-inducible
factor 1.  Cell Growth Differ 2001, 12:363-369.
6. Frost LW, Neeley YX, Schafer R, Gibson LF, Barnett JB: Propanil
inhibits tumor necrosis factor-a production by reducing
nuclear levels of the transcription factor, nuclear factor-kap-
paB in the macrophage cell line, IC-21.  Toxicol Appl Pharmacol
2001, 172:186-193.
7. Xie YC, Schafer R, Barnett JB: The immunomodulatory effects of
the herbicide propanil on murine macrophage interleukin-6
and tumor necrosis factor-alpha production.  Toxicol Appl Phar-
macol 1997, 145:184-191.
8. Zhao W, Schafer R, Cuff CF, Gandy J, Barnett JB: Changes in Pri-
mary and Secondary Lymphoid Organ T-Cell Subpopula-
tions Resulting from Acute In Vivo Exposure to Propanil.  J
Toxicol Environmental Health 1995, 46:171-181.
9. Jiang BH, Semenza GL, Bauer C, Marti HH: Hypoxia-inducible fac-
tor 1 levels vary exponentially over a physiologically relevant
range of O2 tension.  Am J Physiol 1996, 271:C1172-C1180.
10. Maxwell PH, Dachs GU, Gleadle JM, Nicholls LG, Harris AL, Stratford
IJ, Hankinson O, Pugh CW, Ratcliffe PJ: Hypoxia-inducible factor-
1 modulates gene expression in solid tumors and influences
both angiogenesis and tumor growth.  Proc Natl Acad Sci U S A
1997, 94:8104-8109.
11. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu
MM, Simons JW, Semenza GL: Modulation of hypoxia-inducible
factor 1alpha expression by the epidermal growth factor/
phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in
human prostate cancer cells: implications for tumor angio-
genesis and therapeutics.  Cancer Res 2000, 60:1541-1545.
12. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL: HER2
(neu) signaling increases the rate of hypoxia-inducible factor
1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-
mediated vascular endothelial growth factor expression.  Mol
Cell Biol 2001, 21:3995-4004.
13. Huang LE, Gu J, Schau M, Bunn HF: Regulation of hypoxia-induc-
ible factor 1alpha is mediated by an O2-dependent degrada-
tion domain via the ubiquitin-proteasome pathway.  Proc Natl
Acad Sci U S A 1998, 95:7987-7992.
14. Salceda S, Caro J: Hypoxia-inducible factor 1alpha (HIF-1alpha)
protein is rapidly degraded by the ubiquitin-proteasome sys-
tem under normoxic conditions. Its stabilization by hypoxia
depends on redox-induced changes.  J Biol Chem 1997,
272:22642-22647.
15. Xie YC, Schafer R, Barnett JB: Inhibitory effect of 3,4-dichloro-
propionaniline on cytokine production by macrophages is
associated with LPS-mediated signal transduction.  J Leukoc
Biol 1997, 61:745-752.
16. Zhao W, Schafer R, Barnett JB: Cytokine production by C57Bl/6
mouse spleen cells is selectively reduced by exposure to pro-
panil.  J Toxicol Environ Health 1996, 55:107-120.
17. Zhao W, Schafer R, Barnett JB: Propanil affects transcriptional
and posttranscriptional regulation of IL-2 expression in acti-
vated EL-4 cells.  Toxicol Appl Pharmacol 1999, 154:153-159.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/6/204/pre
pub
Expression of HIF-1α was specifically induced by hypoxia, and inhibited by the treatment of DCPAFigure 7
Expression of HIF-1α was specifically induced by hypoxia, 
and inhibited by the treatment of DCPA. DU145 (A) and PC-
3 (B) cells were cultured in complete medium in the pres-
ence of 0, 75, or 150 μM DCPA for 24 h, followed by the 
incubation with 20% or 1% O2 (hypoxia) for 6 h. Total cellu-
lar protein extracts were prepared from these cells, and aliq-
uots of the extracts were used for the immunoblotting 
analysis.
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